Brief: Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
20/03/2025 20:47
March 20 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS REACQUIRES LICENSING RIGHTS TO IMCIVREE® (SETMELANOTIDE) IN CHINA WITH TERMINATION OF AGREEMENT WITH RARESTONE LTD. RHYTHM PHARMACEUTICALS INC - UNDER AGREEMENT, CO TO REPAY $6.3 MILLION TO RARESTONE RHYTHM PHARMACEUTICALS- TO RETURN ALL RARESTONE SHARES ACQUIRED UNDER ORIGINAL AGREEMENT FOR NO ADDITIONAL CONSIDERATION Source text: ID:nGNXbNLkck Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand